natgillin/translations-raw huggingface dataset:
Accordingly, the present invention relates to a liquid formulation comprising the DL-lactic acid addition salt, the glutaric acid addition salt, the L-aspartic acid addition salt or the glutamic acid addition salt of 4-[2-(4-methylphenylsulfanyl)phenyl]piperidine. 
PATENTNI ZAHTJEVI 1. Tekući farmaceutski oblik koji sadrži sol 4-[2-(4-metilfenilsulfanil)fenil|piperidina izabranu između adicijske soli DL-mliječne kiseline, adicijske soli glutarne kiseline, adicijske kiseline L-asparaginske kiseline i adicijske soli glutaminske kiseline.
Accordingly, the present invention relates to hydrogen sulfide scavenging additive which scavenges hydrogen sulfide in hydrocarbons by forming water soluble scavenged products which get easily separated from the hydrocarbon even at acidic pH and that's too without causing any fouling and decomposition problems, wherein the scavenging additive consists of aldehyde and polyethylene glycol [PEG], and wherein aldehyde is glyoxylic acid. 
HR P20130378 T1 PATENTNI ZAHTJEVI Aditiv za čišćenje vodik sulfida sposoban čistiti vodik sulfid u ugljikovodicima stvaranjem proizvoda za čišćenje topivih u vodi koji su sposobni odvojiti se od ugljikovodika čak i u kiselom pH bez stvaranja problema onečišćenja i raspadanja, pri čemu se aditiv za čišćenje sastoji od aldehida 1 polietilen glikola (PEG), i pri čemu navedeni je aldehid glioksilna kiselina.
A pharmaceutical formulation comprising the anti-FcRH5 antibody of any one of claims 1-6 and/or the immunoconjugate of claim 10 or 11 and a pharmaceutically acceptable carrier, and optionally further comprising an additional therapeutic agent. 
Farmaceutska formulacija, naznačena time, da sadrži protutijelo anti-FcRH5 u skladu s bilo kojim od patentnih zahtjeva 8 do 14 i/ili imunokonjugat u skladu s patentnim zahtjevom 17 ili 18, i jedan farmaceutski prihvatljiv nosač, te prema potrebi nadalje sadrži jedno dodatno terapeutsko sredstvo.
in an amount from about 10% to about 12% by weight and the formulation further comprises: 
(a) u količini od 10% do 12% po masi i formulacija dodatno obuhvaća:
The organic phase was dried over magnesium sulfate, and the solvent was evaporated off. 
Organska faza je osušena na magnezijevom sulfatu, a otapalo je upareno.
In another embodiment, the antigen recognition complex is constitutively expressed on the surface of the cell. 
T-stanica prema zahtjevu 6 ili zahtjevu 7, naznačena time da je ko-stimulacijski ligand konstitutivno eksprimiran na površini T-stanice.
(b1) Oligo is an oligomeric segment comprising polypropylene oxide, polyethylene oxide, or polytetramethyleneoxide and having a theoretical molecular weight of from 1,000 to 3,000 Daltons; 
Oligo je oligomerni segment koji sadrži polipropilen oksid, polietilen oksid, ili politetrametilenoksid i ima teorijsku molekulsku masu od 500 do 3000 Daltona;
The product was dissolved in a concentrated aqueous sodium hydroxide solution (30%) and the resulting solution extracted with a mixture of dichloromethane/methanol/ concentrated aqueous ammonia solution in the proportions 100/0/0 to 70/30/3. 
Produkt se otopi u koncentriranoj vodenoj otopini natrijevog hidroksida (30 %), a dobivenu otopinu ekstrahira smjesom diklormetan/metanol/koncentrirana vodena otopina amonijaka, u odnosima od 100/0/0 do 70/30/3.
A sealable container according to embodiment 1, 2 or 3, wherein the adhesive is an adhesive based on a polymeric substrate or a polyethylene(PE) or PE co-polymer based material. 
Posuda prema Zahtjevu 1, 2 ili 3, gdje je ljepilo temeljeno na polimernom supstratu ili polietilenu (PE) ili materijalu temeljenom na PE kopolimerima.
The immortalized human blood cell according to claim 39 or 40, being derived from the cell line ATCC CCL-243 (K652). 
Imortalizirana stanica iz ljudske krvi u skladu s patentnim zahtjevom 39 ili 40, naznačena time što je dobivena iz stanične linije ATCC CCL-243 (K652).
A developer supply container (1) according to Claim 1 or 2, wherein said drive converting portion (2d, 3b) converts the rotational force so that an internal pressure of at least said developer discharging chamber (3h) changes between a pressure lower than an ambient pressure and a pressure higher than the ambient pressure with the reciprocation of said pump portion (2b). 
Spremnik za nadopunjavanje razvijača u skladu s patentnim zahtjevima 1 ili 2, naznačen time što navedeni dio za pretvorbu pogona (2d, 3b) pretvara silu vrtnje na takav način da se unutarnji tlak u navedenoj komori za ispuštanje Tazvijača (3h) mijenja između tlaka nižeg od tlaka okoliša i tlaka višeg od tlaka okoliša.
The lipid particle of claim 5, wherein the particle further comprises a non-cationic lipid, preferably selected from the group consisting of a phospholipid, cholesterol or cholesterol derivative, or a mixture of a phospholipid and cholesterol or cholesterol derivative, wherein the phospholipid preferably comprises dipalmitoylphosphatidylcholine (DPPC), distearoylphosphatidyl-choline (DSPC), or a mixture thereof. 
Čestica lipida u skladu s patentnim zahtjevom 5, naznačena time, da čestica nadalje sadrži ne-kationski lipid, poželjno odabran iz skupine koja se sastoji od fosfolipida, kolesterola ili kolesterol derivata, ili smjese fosfolipida i kolesterola ili kolesterol derivata, pri čemu fosfolipid poželjno sadrži dipalmitoilfosfatidilkolin (DPPC), distearoilfosfatidil-kolin (DSPO), ili njihovu smjesu.
The buprenorphine patches within the kit may be coded (i.e., color, numerical by day, or numerical by dose, etc.) 
Flasteri s buprenorfinom mogu unutar kompleta biti pacijentu označeni (bojom, brojčano (dani) ili brojčano (doza), itd.
In further embodiments, said muscular dystrophy is selected from the group consisting of Duchenne muscular dystrophy, Becker muscular dystrophy, limb girdle muscular dystrophy, congenital muscular dystrophy, facioscapulohumeral muscular dystrophy, myotonic muscular dystrophy, oculopharyngeal muscular dystrophy, distal muscular dystrophy, and Emery-Dreifuss muscular dystrophy. 
VBPI5 ili VBP6 za uporabu u skladu s patentnim zahtjevom 1, pri čemu je navedena mišićna distrofija izabrana iz grupe koja sadrži Duchenne mišićnu distrofiju, mišićnu distrofiju donjih udova, kongentialnu mišićnu distrofiju, facioskapulohumeralnu mišićnu distrofiju, miotoničnu mišićnu distrofiju, okulofaringealnu mišićnu distrofiju, distalnu mišićnu distrofiju i Emery-Dreifuss mišićnu distrofiju.
The process according to claim 1, wherein the polyethylene composition satisfies the relationship: wt % PCR≤74−(14.4×HL275A), wherein wt % PCR is the proportion in weight percent of the high density polyethylene post consumer resin in the polyethylene composition relative to the total weight of the polyethylene composition and HL275A is the HL275 of fraction A of the virgin Ziegler-Natta catalyzed polyethylene resin as determined according to ISO 1133, condition G, at 190° C. and under a load of 21.6 kg wherein a die of 2.75 mm broad was used. 
težinu sastava. Postupak prema zahtjevu 1 naznačeno time da polietilenski sastav zadovoljava odnos: 0% PCR<74 - (14.4 x HL.275A), naznačeno time da 0% PCR je razmjer težinskog udjela recikliranog polietilena visoke gustoće u sastavu u odnosu na ukupnu težinu sastava, te HL275A je HL275 frakcije A neobrađene Ziegler-Natta katalizirane polietilenske smole utvđrene prema ISO 1133, uvjet G, na 190"C 1 pod opterećenjem od 21.6kg osim što je korišten kalup širine 2.75mm.
The compound for use according to claim 1, wherein the inflammatory bowel disease is ulcerative colitis, Crohn's disease, intestinal tuberculosis, ischemic colitis or intestinal ulcer associated with Behcet disease. 
Spoj namijenjen upotrebi u skladu s patentnim zahtjevom 1, naznačen time što je upalna bolest crijeva ulcerozni kolitis, Crohnova bolest, tuberkuloza crijeva, ishemični kolitis ili vrijed na crijevima povezan s Behgetovom bolešću.
A tube of this type has a diameter of approximately 3 mm and is relatively flexible. 
Cijev ove vrste ima promjer od približno 3 mm i relativno je fleksibilna.
The process of claim 1 wherein step d) is effected at 40 to 70°C, preferably at 60°C. 
Postupak iz patentnog zahtjeva 1 naznačeno time da je korak d) proveden pri 40 do 70°C, preferirano pri 60°C.
The process of claim 1, wherein step (1x) further comprises the conversion of compound (VII) to compound (X) via carboxylic acid (1c), by 
Postupak prema zahtjevu 1, gdje korak (1x) dalje sadrži konverziju spoja (VII) do spoja (X) preko karboksilne kiseline (1c), pomoću
The system according to claim 1, wherein at least one user terminal is a self-service terminal to enable to the user food and/or drink orders within a gastro environment. 
Sustav za igranje sukladno bilo kojem od prethodnih patentnih zahtjeva, pri čemu je najmanje jedan korisnički terminal (2) samoposlužni terminal koji omogućuje korisnikove narudžbe za hranu i/ili piće iz gastro okruženja.
After adsorption of pravastatin salt, the column was eluted with 4 L of water:acetone (8:2) and the fractions containing pravastatin were combined (1760 ml), reduced in volume, and pravastatin salt (64.8 g) was isolated. 
Nakon adsorpcije soli pravastatina, kolona je isprana s 4 L voda:aceton (8:2), zatim su sjedinjene frakcije pravastatina (1760 ml), smanjen im je volumen i izolirana je sol pravastatina (64.8 g).
A compound of Formula (I) according to claims 1 or 2 wherein both R1 and R2 are hydrogen or one is hydrogen and the other is methyl, ethyl, propyl, tert-butyl,optionally substituted with hydroxy or fluorine, C3-C6 cycloalkyl, optionally substituted with hydroxy or fluorine. 
Spoj formule (I) prema patentnim zahtjevima 1 ili 2 naznačeno time da oba R' i R jesu vodik ili jedan jest vodik a drugi je metil, etil, propil, fert-butil, koji može biti supstituiran s hidroksi ili fluorom, C3-Cg cikloalkil, koji može biti supstituiran s hidroksi ili fluorom.
The B7-H3 binding molecule of claim 1 or 2, wherein said B7-H3 binding molecule binds to B7-H3 that is endogenously expressed on the surface of a cancer cell. 
Molekula koja se veže na B7-H3 u skladu s patentnim zahtjevom 1 ili 2, naznačena time što se navedena molekula koja se veže na B7-H3 veže na B7-H3 koji se endogeno eksprimira na površini stanice raka.
correlating the response of the patients treated with the HER dimerization inhibitor to the level of expression of the marker protein encoded by the marker gene or the combination of marker proteins encoded by the marker genes determined in step a) thereby determining the threshold value. 
uspoređivanja uzajamne veze reakcije pacijenata liječenih inhibitorom HER dimerizacije s razinom ekspresije marker-proteina kodiranog marker-genom ili kombinacijom marker-proteina kodiranih marker-genima određenima u koraku a), te time utvrđivanja granične vrijednosti.
The fan assembly of claim 13, wherein the interior passage is shaped to divide the received air flow into two air streams each flowing along a respective side of the opening. 
Ventilatorski sustav prema zahtjevu 16, gdje je unutarnji prolaz (204) oblikovan tako da dijeli primljenu struju zraka u dvije struje od kojih svaka ide duž odgovarajuće strane otvora (38).
The method according to the invention is characterized by the fact that elementary selenium and/or sulphur vapor is guided past from a first or second source located inside and/or outside the processing chamber by means of a carrier gas which is in particular inert under rough vacuum conditions to overpressure conditions on the or on each precursor layer, in order for said layer to react chemically in a targeted manner with selenium or sulphur. 
Postupak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što se kemijsku reakciju selenija i/ili sumpora s metalnim slojem provodi pod ukupnim tlakom u radnoj komori (14) u rasponu od uvjeta grubog vakuuma, tlaka okoliša do predtlaka i/ili pod parcijalnim tlakom para selenija ili sumpora u rasponu od otprilike 0,001 mbar (0,1 Pa) do otprilike 100 mbar (10 kPa).
The apparatus of claim 1, wherein, when the intra prediction mode is a planar mode, the prediction block generator (250) generates the prediction block using a corner reference pixel, a left reference pixel and an upper reference pixel. 
Uređaj iz zahtjeva 1, pri čemu se, kada je intrapredikcijski režim planarni režim, referentni pikseli predikcijskog bloka generiraju pomoću kutnog referentnog piksela, lijevog referentnog piksela i gornjeg referentnog piksela.
contacting the water and/or sludge and/or sediment of step a) with the at least one surface-treated calcium carbonate of step b) for obtaining a composite material of surface-treated calcium carbonate and impurities, wherein the surface-treated calcium carbonate comprises a surface-modified calcium carbonate that has been processed with cationic polymers through an additional treatment step, wherein the surface-modified calcium carbonate is obtained by reacting a natural calcium carbonate and/or precipitated calcium carbonate with an acid and with carbon dioxide prior to the preparation of the surface-treated calcium carbonate, wherein the carbon dioxide is formed in situ by the acid treatment and/or is supplied from an external source. 
kontaktiranje vode i/ili mulja i/ili sedimenta iz koraka a) s najmanje jednim površinski obrađenim kalcijevim karbonatom iz koraka b) radi dobivanja kompozitnog materijala s površinski obrađenim kalcijevim karbonatom i nečistoćama, pri čemu najmanje jedan površinski obrađen kalcijev karbonat sadrži površinski izmijenjen kalcijev karbonat koji je bio obrađen s kationskim polimerima kroz dodatni korak obrade, te pri čemu se površinski izmijenjen kalcijev karbonat dobiva reakcijom prirodnog kalcijevog karbonata i/ili istaloženog kalcijevog karbonata s kiselinom i s ugljikovim dioksidom prije pripremanja površinski obrađenog kalcijevog karbonata, pri čemu ugljikov dioksid nastaje in situ pomoću obrade s kiselinom i/ili de dobavlja iz vanjskog izvora.
(c9) an antibody L chain consisting of the amino acid sequence of SEQ ID NO: 34 (L408-k); and (c10) an antibody L chain consisting of the amino acid sequence of SEQ ID NO: 171 (L180-k). 
(c9) L-lanac protutijela koji se sastoji od aminokiselinske sekvence SEQ ID NO: 34; 1 (c10) L-lanac protutijela koji se sastoji od aminokiselinske sekvence SEQ ID NO: 171. HR P20180421 T1
The method of claim 7, wherein the water activity (Aw) of the dry glassy stabilizing composition is less than 0.3. 
Postupak pripreme sukladno patentnom zahtjevu 7, naznačen time da aktivnost vode (Aw) suhe stabilizirajuće kompozicije je Aw<0,3 ili niži.
The reaction was cooled to rt and the DMF was removed in vacuo. 
Smjesa je ohlađena do sobne temperature i DMF je uklonjen in vacuo.
A liquid long acting injectable formulation for use according to claim 8, wherein the combating of ectoparasites and/or endoparasites has a therapeutic effect for a period of time selected from the group consisting of at least about four months to about one year, at least about four months to about six months and at least about three months to about five months. 
Tekuća imjektibilna formulacija s produljenim djelovanjem za uporabu prema zahtjevu 8, naznačena time, da suzbijanje ektoparazita i/ili endoparazita ima terapeutski učinak za vremenski period koji je odabran iz skupine koju čine: najmanje oko četiri mjeseca do oko godine dana, najmanje oko četiri mjeseca do oko šest mjeseci i najmanje oko tri mjeseca do oko pet mjeseci.
at least one active agent selected from opioid analgesics wherein the opioid analgesic is hydromorphone hydrochloride and the dosage form comprises from 1 mg to about 100 mg of hydromorphone hydrochloride; and 
najmanje jedno aktivno sredstvo odabrano od opioidnih analgetika; te pri čemu pripravak sadrži barem oko 80 % (težinski) polietilen oksida.
A display arrangement according to claim 2, further comprising a plurality of image projection units (24; 124; 224) for separately projecting the game result onto a respective facet (22; 122) of the display screen (21; 121; 221). 
Uređaj za prikaz sukladno patentnom zahtjevu 2, naznačen time da nadalje obuhvaća veći broj projekcijskih jedinica (24, 124; 224) za zasebnu projekciju rezultata igre na odgovarajućoj strani (22; 122) zaslona (21; 121;
The blister pack according to claim 10, in which each of said layer located above and said layer located beneath, which are the same or different, comprises a polymer selected from the group consisting of: polyvinyl chloride, polyvinylidene chloride, polypropylene, polyethylene terephthalate, polyacrylate, polyacrylonitrile, cyclic olefins, polystyrenes, polyesters, polyamides, ethylene vinyl alcohol, polyvinyl alcohol and their copolymers. 
Blister pakiranje prema 10. zahtjevu, naznačeno time da svaki od navedena dva sloja (6p, 6c), a koji su isti ili različiti, sadrži polimer odabran iz skupine koja se sastoji od: polivinil klorida, poliviniliden klorida, polipropilena, polietilen tereftalata, poliakrilata poliakrilonitrila, cikličkih olefina, polistirena, poliestera, poliamida, etilen vinil alkohola, polivinil alkohola ili njihovih kopolimera.
The method of claim 1, wherein in said hIL-2 mutein, through the substitution at position 88, an asparagine is exchanged for an amino acid which is selected from the group consisting of: arginine (hIL-2-N88R), glycine (hIL-2-N88G), or isoleucine (hIL-2-N88I). 
pomoću supstitucije na položaju 88 asparagin je zamijenjen sa argininom (hIL-2-N88R), ili sa glicinom (hIL-2-N88G), ili sa izoleucinom (hIL-2-N88I),
a first heavy chain comprising the amino acid sequence of SEQ ID NO:313, a second heavy chain comprising the amino acid sequence of SEQ ID NO:314, and two light chains comprising the amino acid sequence of SEQ ID NO:279. 
prvi teški lanac koji obuhvaća domenu VH koja sadrži aminokiselinsku sekvencu SEQ ID NO:329, i prvi laki lanac koji obuhvaća domenu VL koja sadrži aminokiselinsku sekvencu SEQ ID NO:330,
Acetyl D-Phe Ala In exemplary aspects of the peptide of SEQ ID NO: 140, X10 is Tyr, the peptide comprises at position 40 an amino acid covalently attached to a C12 to C18 acyl or alkyl group, and the peptide optionally comprises Gly at position 41. 
Xyo je aminokiselina kovalentno vezana na C12-C18 acilnu ili alkilnu skupinu, ili kada je X;g Tyr, peptid na položaju 40 sadrži aminokiselinu kovalentno vezanu na C12 do C18 acilnu ili alkilnu skupinu, gdje peptid može sadržavati Gly na položaju 41.
A pharmaceutical composition according to claim 3, wherein the active agent comprises at least about 2.4% (by weight) of the dosage form. 
Oblik doziranja s produljenim otpuštanjem prema zahtjevima od 1 do 11, naznačen time da sastojak sadrži barem oko 80 % (po težini) polietilen oksida.
Examples 4 and 5) using a compound of this invention in place of compound 9 of that publication, and may be lyophilized as described in that publication. 
Primjeri 4 1 5) upotrebom spoja iz ovog izuma umjesto spoja 9 1z prijave, i može se lipofilizirati kao što je opisano u prijavi.
Such surface-reacted products may, for example, be prepared according to WO 00/39222, WO 2004/083316, WO 2005/121257, WO 2009/074492, unpublished European patent application with filing number 09162727.3, and unpublished European patent application with filing number 09162738.0. Said calcium-carbonate containing material of step a) preferably contains at least 50%, preferably at least 90% by weight of calcium carbonate relative to the total weight of said calcium-carbonate containing material. 
Postupak prema zahtjevu 1, naznačen time da je kalcijev karbonat iz navedenog materijala koji sadrži kalcijev karbonat iz koraka a) odabran iz skupine koja sadrži prirodni usitnjeni kalcijev karbonat, dolomit, nataloženi kalcijev karbonat i njihove smjese, te navedeni materijal koji sadrži kalcijev karbonat poželjno sadrži barem 50 %, poželjno barem 90 % težinski kalcijevog karbonata u odnosu na ukupnu težinu navedenog materijala koji sadrži kalcijev karbonat.
The jar 10 includes a hollow, cylindrical interior having formed on its interior surface a latching groove 38 at the upper end of latch sub 14 . 
Udarac 10 ima šuplju cilindričnu unutrašnjost koja je oblikovana na unutrašnjoj površini zabravljujućeg žlijeba 38 na gornjem kraju elementa 14 zasuna.
The method of embodiment 29, further comprising, prior to (c), computationally removing allele frequencies for polymorphisms identified has being homozygous in both the fetus and the pregnant individual. 
Postupak prema patentnom zahtjevu 1, naznačen time što nadalje sadrži, prije postupka (c), računalno uklanjanje učestalosti alela za polimorfizme koji su identificirani kao homozigotni i kod fetusa i kod trudne osobe.
The co-crystal of claim 3, having a DSC peak in its DSC thermogram at about 195° C. and about 245° C. 
ima maksimum DSC u svom DSC termogramu na otprilike 195 °C i otprilike 245 °C.
a replacement of a genomic DNA of a mouse IL-4 gene at an endogenous mouse IL-4 locus with a genomic DNA of a human IL-4 gene to form a humanized IL-4 gene, wherein the genomic DNA of the mouse IL-4 gene comprises the ATG initiation codon of exon 1 through exon 4 of the mouse IL-4 gene, and the genomic DNA of the human IL-4 gene comprises the ATG initiation codon of exon 1 through exon 4 of the human IL-4 gene, and wherein expression of the humanized IL-4 gene is under control of the mouse IL-4 promoter at the endogenous mouse IL-4 locus, and 
Glodavac u skladu s patentnim zahtjevom 1, naznačen time što glodavac sadrži zamjenu genomskog fragmenta gena za glodavački IL-4 na lokusu za endogeni glodavački IL-4 genomskim fragmentom gena za ljudski IL-4 kako bi se dobilo gen za humanizirani IL-4, gdje genomski fragment gena za glodavački IL-4 sadrži početni kodon ATG egzona 1 do egzona 4 gena za glodavački IL-4, a genomski fragment gena za ljudski 1I-4 sadrži početni kodon ATG egzona 1 do egzona 4 gena za ljudski IL-4, te gdje je eksprimiranje gena za humanizirani IL-4 pod kontrolom regulacijskih elemenata glodavačkog IL-4 na lokusu za endogeni glodavački IL-4.
ix) any colonies of Candida spp. will appear white. The platform according to claim 1, wherein said antibacterial antibiotic is selected from the group consisting of Amoxicillin, cluvulanic acid/ampicillin, sulbactam, a fluoroquinolone, Sulphamethoxazole, trimethoprim, an oral cephalosporin, Nitrofurantoin and Fosfomycin (fosfomycin-trometerole). 
Trovafloksacin, Tilozin, Vankomicin, Virginiamicin, Vorikonazol, poželjno se izabire iz grupe koja obuhvaća amoksicilin, klavulansku kiselinu/ampicilin, sulbaktam, fluorokinolon, Sulfametoksazol, trimetoprim, oralni cefalosporin, Nitrofurantoin i Fosfomicin (fosfomicin-trometamol) ili se izabire iz grupe koja obuhvaća trimetoprim, sulfametoksazol, ampicilin, nitrofurantoin i mecilinam (amdinocilin) te njihove kombinacije.
A is C1 to C6 optionally substituted alkyl, wherein said C1 to C6 optionally substituted alkyl can be saturated or unsaturated, and wherein A may or may not be present; Y is selected from the group consisting of ketal, ester, optionally substituted carbamate, ether, and optionally substituted amide; and 
Y je odabran iz skupine koja se sastoji od ketala, estera, karbamata po izboru supstituiranog sa zasićenim ili nezasićena C, do Cg alkilna skupina, eter i amid, po izboru supstituiran sa zasićenom ili nezasićenom C; do C% alkilnom skupinom
The sealing material 8 can be attached to the outer surface of the capsule by gluing, welding or also mechanically (press-fitting, crimping, etc.). 
Materijal za brtvljenje 8 može se nanijeti na vanjsku površinu čahure lijepljenjem, zavarivanjem ili također mehanički (utiskivanjem, uvijanjem i tako dalje).
The treatment and/or prevention method according to claim 22 or 23, wherein the cancer is selected from the group consisting of lung cancer, prostate cancer, thyroid cancer, stomach cancer, liver cancer, ovarian cancer, colon cancer, breast cancer, pancreatic cancer, renal cancer, uterine cancer, melanoma, fibrosarcoma, glioblastoma, and blood cell cancer. 
Antitijelo ili proizvod za primjenu prema bilo kojem od patentnih zahtjeva 13 do 15, gdje je rak odabran iz grupe koja se sastoji od raka pluća, raka prostate, tiroidnog raka, raka želuca, raka jetre, raka jajnika, raka debelog crijeva, raka dojke, raka gušterače, raka materice, melanoma, glioblastoma, i raka krvnih stanica..